First Forxiga follow-on Dapapro listed at KRW 684

...price set at 90% of the original

A prodrug that has a different chemical structure with the original

Expected to occupy market with the early release

The first follow-on of the antidiabetic SGLT-2 inhibitor ‘Forxiga Tab (dapagliflozin, AstraZeneca)’ will be listed at ‘Dapapro Tab’ with reimbursement at KRW 684 on December 1.

 

The price has been set at 90% of the original due to premium pricing as a data submission drug due to salt modification, etc.

 

Dapapro Tab succeeded in avoiding the duration of the substance patent as a prodrug that has a different chemical structure from the original.

 

According to industry sources on the 28th, Dapapro Tab will be listed for reimbursement at KRW 684 on December 1.

 

This is 10% lower than the KRW 760 set for Forxiga.

 

In general, generics are listed at 53.55% of the original’s ceiling price, but as a data submission drug, the price was set at 90% of the original.

 

Dapapro's ceiling price will be maintained as is until another generic with the same ingredient is listed.

 

Until February, the release of Dapapro had been unclear until before the substance patent expiry.

 

Dong-A ST had filed a claim to confirm the scope of rights for Forxiga’s substance patent, claiming that its drug does not impede the scope of rights of Forxiga’s substance patent, but the Patent Court of Korea reversed the decision of the Intellectual Property Trial and Appeal Board that had admitted the company’s claim.

 

Nevertheless, Dong-A ST newly challenged the patent again and received an admission in the trial to confirm the scope of rights on the 2nd.

 

In other words, the court accepted the claim that the 917 days added to the patent term for Forxiga’s substance patent does not apply to Dong-A ST’s product.

 

Based on this, Dong-A ST started its reimbursement process and succeeded in listing its drug with reimbursement on the 1st of the following month.

 

Forxiga’s substance patent will expire in April next year, and if Dapapro is released with reimbursement, it will be marketed before the expiry of the substance patent.

 

With Dong-A ST planning to release Dapapro by February next year, the product is expected to be the first drug sold among Forxiga follow-on drugs.

 

Also, it will be the first SGLT-2 class follow-on to be released into the market as well.

 

Also, Dong-A ST owns its new antidiabetic drug ‘Suganon.’ The addition of the SGLT-2 antidiabetic Dapapro to its portfolio is expected to expand the company’s share in the domestic diabetic drug market.

 

In particular, with Dapapro being released earlier than the generic versions of Forxiga, it is expected to further occupy the follow-on drug market.